Lonza sells CHI to Lone Star Funds: the legal advisors
Lonza entered into a definitive agreement for the sale of the Capsules & Health Ingredients (CHI) business to Lone Star Funds, at an enterprise value of CHF 2.3 billion (USD 3 billion).
In connection with the deal Lenz & Staehelin advised Lone Star Funds, while Advestra represented Lonza, working alongside international lead counsel Linklaters and Lonza’s in-house legal counsels Daniel Blaettler (general counsel corporate, finance & transactions), Sarah Chevalley (associate general counsel) andAlbert Pereda (associate general counsel).
The transaction
Pursuant to the deal, Lonza will receive upfront proceeds of CHF 1.7 billion (USD 2.2 billion) and retain a 40% stake in CHI post-closing. The transaction, expected to close in the second half of 2026, marks the last step to complete Lonza’s portfolio transformation into a pure-play contract development and manufacturing organization.
The Advestra team
The Advestra team on the matter included Andreas Hinsen (pictured), Anna Capaul, Daryana Maurer and Jana Wildberger (all corporate/M&A) as well as Sharon Spring (employment).
The Lenz & Staehelin team
Tino Gaberthüel and Simone Ehrsam (both corporate and M&A) led the Lenz & Staehelin team on the matter, working alongside Raphael Fries, Nils Maag (both corporate and M&A), Peter Ling, Lena Dürwald (both IP) and Franziska Stadtherr-Glättli (social security, pension, tax).
